|
5/2025
vol. 112
Review article
Efficacy, Safety, and Impact on the Quality of Life
of Guselkumab in the Treatment of Moderate-to-Severe Plaque
Psoriasis and Psoriatic Arthritis
- Junior Physician, Municipal Specialist Hospital named after G. Narutowicza, Krakow, Poland
- Junior Physician, Stefan Żeromski Specialist Hospital, SP ZOZ, Krakow, Poland
- 6th-Year Medical Student, Andrzej Frycz Modrzewski Krakow University, Krakow, Poland
- Junior Physician, Beskid Oncology Center - Municipal Hospital named after John Paul II, Bielsko-Biala, Poland
- Junior Physician, University Hospital, Krakow, Poland
Dermatol Rev/Przegl Dermatol 2025, 112, 301-305
Online publish date: 2025/12/30
Get citation
PlumX metrics:
1. Machado Á., Torres T.: Guselkumab for the treatment of psoriasis. BioDrugs 2018, 32, 119-128. 2.
Al-Salama Z.T., Scott L.J.: Guselkumab: a review in moderate to severe plaque psoriasis. Am J Clin Dermatol 2018, 19, 907-918. 3.
Tokuyama M., Mabuchi T.: New treatment addressing the pathogenesis of psoriasis. Int J Mol Sci 2020, 21, 7488. 4.
Mease P.J., Rahman P., Gottlieb A.B., Kollmeier A.P., Hsia E.C., Xu X.L., et al.; DISCOVER-2 Study Group: Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 2020, 395, 1126-1136. Erratum in: Lancet 2020, 395, 1114 5.
Deodhar A., Helliwell P.S., Boehncke W.H., Kollmeier A.P., Hsia E.C., Subramanian R.A., et al.; DISCOVER-1 Study Group: Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 2020, 395, 1115-1125. Erratum in: Lancet 2020, 395, 1114. 6.
Megna M., Balato A., Raimondo A., Balato N.: Guselkumab for the treatment of psoriasis. Expert Opin Biol Ther 2018, 18, 459-468. 7.
Nakamura M., Lee K., Jeon C., Sekhon S., Afifi L., Yan D., et al.: Guselkumab for the treatment of psoriasis: a review of phase III trials. Dermatol Ther (Heidelb) 2017, 7, 281-292. 8.
Hampton P., Borg E., Hansen J.B., Augustin M.: Efficacy of brodalumab and guselkumab in patients with moderate-to-severe plaque psoriasis who are inadequate responders to ustekinumab: a matching adjusted indirect comparison. Psoriasis 2021, 11, 123-131. 9.
Thilakarathne P., Schubert A., Peterson S., Noel W., Patel B., Hassan F.: Comparing efficacy of guselkumab versus ustekinumab in patients with psoriatic arthritis: an adjusted comparison using individual patient data from the DISCOVER and PSUMMIT trials. Rheumatol Ther 2024, 11, 457-474. 10.
Sbidian E., Chaimani A., Garcia-Doval I., Doney L., Dressler C., Hua C., et al.: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev 2022, 5, CD011535. Update in: Cochrane Database Syst Rev 2023, 7, CD011535. 11.
Blauvelt A., Papp K., Gottlieb A., Jarell A., Reich K., Maari C., et al.; IXORA-R Study Group: A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. Br J Dermatol 2020, 182, 1348-1358.
Copyright: © 2025 Polish Dermatological Association. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License ( http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license. |
|
